Navigation Links
Celebrex Shows Potential in Preventing Some Skin Cancers: Study
Date:11/29/2010

By Steven Reinberg
HealthDay Reporter

MONDAY, Nov. 29 (HealthDay News) -- The prescription painkiller Celebrex might help prevent non-melanoma skin cancers, a small study suggests.

But one expert was quick to note that the drug, which is most commonly used to counter the pain of arthritis, has been linked in some studies to an increase in the risk for cardiovascular problems. So it isn't yet clear that Celebrex (celecoxib) is an ideal choice to prevent cancers that could be treated by other means.

"We have a lot of different treatments for non-melanoma skin cancers," noted Dr. Doris Day, a dermatologist at Lenox Hill Hospital in New York City. "I would want more information regarding the mechanism of action of Celebrex, because of the other risks," she said.

The report, funded by the U.S. National Cancer Institute and Pfizer, the maker of Celebrex, is published in the Nov. 29 online edition and the Dec. 15 print issue of the Journal of the National Cancer Institute.

Non-melanoma skin cancers are common, comprising "the most prevalent malignancies in the United States with an incidence equivalent to all other cancers combined," according to study lead author Dr. Craig A. Elmets, a professor of dermatology at the University of Alabama at Birmingham. These tumors include basal cell and squamous cell carcinomas of the skin, which are typically linked to overexposure to UV rays from the sun or indoor tanning booths.

Currently, there are no U.S. Food and Drug Administration (FDA)-approved agents for the prevention of non-melanoma skin cancers, although sunscreens are widely recommended for this purpose, Elmets said. "However, even sunscreens are only modestly effective at preventing non-melanoma skin cancers. The demonstration that celecoxib can prevent these common malignancies heralds an entirely new approach for the prevention of these common malignancies," he said.

For the study, Elmets and colleagues randomly assigned 240 people with precancerous skin lesions called actinic keratoses to treatment with Celebrex or placebo. The researchers looked at the number of new lesions after three, six and nine months of treatment, and again two months after treatment had stopped.

The investigators found that the number of new precancerous lesions in both groups was the same.

However, by the end of the study, patients taking Celebrex had a 59 percent lower risk for non-melanoma skin cancers, compared with patients receiving placebo.

However, the study was stopped early after the FDA found that people in another trial that involved a similar drug had an increased risk for heart attacks. There were no such problems in this trial, the researchers noted, perhaps because the trial lasted only nine months.

In an editorial, Drs. Frank Meyskens Jr. and Christine McLaren, both of the University of California, Irvine, said that the finding that Celebrex helped reduce cancers but not precancerous lesions suggests that different mechanisms may be at work during different stages of tumor development.

Celebrex is one of a class of drugs called COX-2 inhibitors, which also include Bextra (valdecoxib) and Vioxx (rofecoxib). Vioxx was withdrawn from the market in 2004 and Bextra in 2005 because studies had suggested users faced heightened risks for heart attack. Celebrex did not show such a level of heightened risk and has remained on the market.

Commenting on the new study, Day said that even though she would not recommend that people take Celebrex for the sole aim of preventing skin cancer, it could prove an additional benefit for people who are already taking the drug to battle their arthritis pain.

"But for me it wouldn't be a first-line drug for people who have non-melanoma skin cancers, because of the other options and the cardiac risks," she said.

In the future this drug may be useful, at a lower dose, for preventing these cancers while avoiding the cardiac risk, Day added, but "I don't think this is ready for recommendation as a preventive for non-melanoma skin cancers."

More information

For more information on skin cancer, visit the U.S. National Library of Medicine.

SOURCES: Craig A. Elmets, M.D., professor, dermatology, University of Alabama at Birmingham; Doris Day, M.D., dermatologist, Lenox Hill Hospital, New York City; Nov. 29, 2010, Journal of the National Cancer Institute, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Can Celebrex prevent cancer-causing colon polyps?
2. Celebrex Appears Easier on Stomach for Arthritis Patients
3. First blinded study of venous insufficiency prevalence in MS shows promising results
4. People with anxiety disorder less able to regulate response to negative emotions, study shows
5. Poll Shows Eroding Support for Health Reform
6. Protecting patients: Study shows that Johns Hopkins flu vaccination rates twice national average
7. Compound shows promise against intractable heart failure
8. Drama or reality TV: Do medical shows depict proper first aid for seizures?
9. TV Shows Often Botch Proper Seizure Responses
10. UQ research shows canecutters disease on the rise among travelers
11. Brain Scan Shows What Beauty is Worth
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celebrex Shows Potential in Preventing Some Skin Cancers: Study
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , Ginger ... Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport ... attorneys from the firm’s global Life Sciences & Medical Technology Group have been featured ...
(Date:12/8/2016)... ... 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services ... Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) named ...
(Date:12/8/2016)... ... ... Vida Health, the digital health platform that pairs individuals with ... . Other investors include Nokia Growth Partners (NGP) and returning investor Aspect Ventures. Vida ... are managing chronic conditions or simply want to improve their health. Canvas ...
(Date:12/8/2016)... ... , ... Coppin Insurance Agency, an insurance and financial planning firm based in ... area, is embarking on a charity drive with the goal of providing support and ... Food Bank of Southwest Florida works to provide fresh and nutritious food free of ...
(Date:12/7/2016)... Washington,DC (PRWEB) , ... December 07, 2016 , ... ... Forum (NYLF): Medicine will have the unique opportunity to get hands-on experience ... gives high school students an immersive experience to gain invaluable, real-life medical skills ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Valeant Pharmaceuticals International, Inc. (NYSE: ... positive results from a Phase 3, multicenter double-blind, ... and efficacy of IDP-118 (halobetasol propionate and tazarotene) ... Within the Phase 3 study of ... IDP-118 showed statistical significance to vehicle with a ...
(Date:12/8/2016)... , Dec. 8, 2016 True ... that brings leading-edge laboratory services and management expertise ... States , allowing more doctors and patients ... care management solutions. Logo - ... Hospital systems, under pressure to contain costs, ...
(Date:12/8/2016)... -- Information products and services provider Elsevier ... , the world,s largest abstract and citation database of peer-reviewed literature, ... from over 5,000 publishers. The new set of metrics will improve ... when to adjust a journal,s editorial strategy. ... , , CiteScore ...
Breaking Medicine Technology: